TOTAL: $31.85M
Year to Date: $169.08M
Company
(Symbol)#*		 Partner
(Country)		 Amt.
(M)		 Triggering
Event		 Details (Date)
Basilea Pharmaceutica Ltd. (Switzerland; SWX:BSLN) Johnson & Johnson Pharmaceutical Research and Development LLC CHF24 ($19.6) Milestone payment Basilea received the money for the filing of an NDA for ceftobiprole to treat complicated skin and skin structure infections (5/18)
CoGenesys Inc.* PDL BioPharma Inc. and Vegenics Ltd. (Australia) ND Milestone payment CoGenesys achieved milestones for PDL's advancement of a candidate into preclinical testing and based on an agreement with Vegenics in the field of vascular endothelial growth factors (5/23)
CV Therapeutics Inc. (CVTX) Astellas Pharma U.S. Inc. $7 Milestone payment CV received the payment for the filing of an NDA for regadenoson as a stress agent in myocardial perfusion imaging tests (5/15)
Diversa Corp. (DVSA) BASF (Nachrichten/ Aktienkurs) ND Milestone payments Diversa achieved two milestones for completing the initial research phase of their collaboration and moving into the next development stage focused on discovering and optimizing new enzymes (5/16)
Medarex Inc. (MEDX) Amgen Inc. (AMGN) ND Milestone payment Medarex will receive the payment for the advancement of an antibody into a Phase II clinical trial (5/3)
Neose Technologies Inc. (NTEC) Novo Nordisk A/S (Denmark) ND Milestone payment Neose received the payment under a 2003 license agreement for the use of Neose's GlycoPEGylation technology to develop a next-generation version of Factor IX (5/24)
Progenics Pharmaceuticals Inc. (PGNX) Wyeth $4 Milestone payment Progenics received the payment after Wyeth filed for European approval of a subcutaneous formulation of methylnaltrexone for opioid-induced constipation (5/14)
SensiGen LLC* Ann Arbor SPARK $0.25 Investment Ann Arbor SPARK approved the $250,000 investment in SensiGen from the Michigan Pre-Seed Capital Fund (5/15)
Sunesis Pharmaceuticals Inc. (SNSS) Merck & Co. Inc. $1 Milestone payment Sunesis earned the payment for meeting a preclinical milestone in its collaboration to develop oral small-molecule inhibitors of beta-amyloid converting enzyme (5/2)